Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Olivier Le Moal

• Evoke Pharma (NASDAQ:EVOK) said the Canadian Intellectual Property Office granted a patent covering methods of use for nasal delivery of Gimoti's formulation, metoclopramide, to treat diabetic gastroparesis (DG).
• The patent titled “Nasal Formulations of Metoclopramide" expires in 2029, according to the company's July 6 press release.
• Evoke said the new patent corresponds to the two other U.S. patents under the same title that expire in 2029 and 2030, respectively.
• DG is a stomach problem related to diabetes which causes delayed gastric emptying.